Search Results - "Storey, Robert F."

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention by Sibbing, Dirk, Aradi, Daniel, Alexopoulos, Dimitrios, ten Berg, Jurrien, Bhatt, Deepak L., Bonello, Laurent, Collet, Jean-Philippe, Cuisset, Thomas, Franchi, Francesco, Gross, Lisa, Gurbel, Paul, Jeong, Young-Hoon, Mehran, Roxana, Moliterno, David J., Neumann, Franz-Josef, Pereira, Naveen L., Price, Matthew J., Sabatine, Marc S., So, Derek Y.F., Stone, Gregg W., Storey, Robert F., Tantry, Udaya, Trenk, Dietmar, Valgimigli, Marco, Waksman, Ron, Angiolillo, Dominick J.

“…Dual-antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the standard treatment for patients undergoing percutaneous coronary…”
Get full text

Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium by Gorog, Diana A., Storey, Robert F., Gurbel, Paul A., Tantry, Udaya S., Berger, Jeffrey S., Chan, Mark Y., Duerschmied, Daniel, Smyth, Susan S., Parker, William A. E., Ajjan, Ramzi A., Vilahur, Gemma, Badimon, Lina, Berg, Jurrien M. ten, Cate, Hugo ten, Peyvandi, Flora, Wang, Taia T., Becker, Richard C.

“…Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and thromboembolic events, owing to excessive inflammation, endothelial cell activation…”
Get full text

Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy by Sumaya, Wael, Wallentin, Lars, James, Stefan K, Siegbahn, Agneta, Gabrysch, Katja, Bertilsson, Maria, Himmelmann, Anders, Ajjan, Ramzi A, Storey, Robert F

“…Abstract Aims To determine whether fibrin clot properties are associated with clinical outcomes following acute coronary syndrome (ACS). Methods and results…”
Get full text

Expert position paper on air pollution and cardiovascular disease by Newby, David E, Mannucci, Pier M, Tell, Grethe S, Baccarelli, Andrea A, Brook, Robert D, Donaldson, Ken, Forastiere, Francesco, Franchini, Massimo, Franco, Oscar H, Graham, Ian, Hoek, Gerard, Hoffmann, Barbara, Hoylaerts, Marc F, Künzli, Nino, Mills, Nicholas, Pekkanen, Juha, Peters, Annette, Piepoli, Massimo F, Rajagopalan, Sanjay, Storey, Robert F

Get full text

Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention by Aradi, Dániel, Storey, Robert F, Komócsi, András, Trenk, Dietmar, Gulba, Dietrich, Kiss, Róbert Gábor, Husted, Steen, Bonello, Laurent, Sibbing, Dirk, Collet, Jean-Philippe, Huber, Kurt

Get full text

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial by Wallentin, Lars, Prof, James, Stefan, MD, Storey, Robert F, MD, Armstrong, Martin, PhD, Barratt, Bryan J, PhD, Horrow, Jay, MD, Husted, Steen, MD, Katus, Hugo, Prof, Steg, P Gabriel, Prof, Shah, Svati H, MD, Becker, Richard C, Prof

“…Summary Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of…”
Get full text

Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction by Montalescot, Gilles, van 't Hof, Arnoud W, Lapostolle, Frédéric, Silvain, Johanne, Lassen, Jens Flensted, Bolognese, Leonardo, Cantor, Warren J, Cequier, Ángel, Chettibi, Mohamed, Goodman, Shaun G, Hammett, Christopher J, Huber, Kurt, Janzon, Magnus, Merkely, Béla, Storey, Robert F, Zeymer, Uwe, Stibbe, Olivier, Ecollan, Patrick, Heutz, Wim M.J.M, Swahn, Eva, Collet, Jean-Philippe, Willems, Frank F, Baradat, Caroline, Licour, Muriel, Tsatsaris, Anne, Vicaut, Eric, Hamm, Christian W

“…This study compared administration of the antiplatelet agent ticagrelor in the ambulance with administration in the cath lab in patients with ST-segment…”
Get full text

Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis by Andreotti, Felicita, Rocca, Bianca, Husted, Steen, Ajjan, Ramzi A, ten Berg, Jurrien, Cattaneo, Marco, Collet, Jean-Philippe, De Caterina, Raffaele, Fox, Keith A A, Halvorsen, Sigrun, Huber, Kurt, Hylek, Elaine M, Lip, Gregory Y H, Montalescot, Gilles, Morais, Joao, Patrono, Carlo, Verheugt, Freek W A, Wallentin, Lars, Weiss, Thomas W, Storey, Robert F

Get full text

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis by Rocca, Bianca, Fox, Keith A A, Ajjan, Ramzi A, Andreotti, Felicita, Baigent, Colin, Collet, Jean-Philippe, Grove, Erik L, Halvorsen, Sigrun, Huber, Kurt, Morais, João, Patrono, Carlo, Rubboli, Andrea, Seljeflot, Ingebjorg, Sibbing, Dirk, Siegbahn, Agneta, Ten Berg, Jurrien, Vilahur, Gemma, Verheugt, Freek W A, Wallentin, Lars, Weiss, Thomas W, Wojta, Johann, Storey, Robert F

Get full text

Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease by Capodanno, Davide, Bhatt, Deepak L., Eikelboom, John W., Fox, Keith A. A., Geisler, Tobias, Michael Gibson, C., Gonzalez-Juanatey, Jose Ramon, James, Stefan, Lopes, Renato D., Mehran, Roxana, Montalescot, Gilles, Patel, Manesh, Steg, P. Gabriel, Storey, Robert F., Vranckx, Pascal, Weitz, Jeffrey I., Welsh, Robert, Zeymer, Uwe, Angiolillo, Dominick J.

“…Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks…”
Get full text

P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention by Capodanno, Davide, Baber, Usman, Bhatt, Deepak L., Collet, Jean-Philippe, Dangas, George, Franchi, Francesco, Gibson, C. Michael, Gwon, Hyeon-Cheol, Kastrati, Adnan, Kimura, Takeshi, Lemos, Pedro A., Lopes, Renato D., Mehran, Roxana, O’Donoghue, Michelle L., Rao, Sunil V., Rollini, Fabiana, Serruys, Patrick W., Steg, Philippe G., Storey, Robert F., Valgimigli, Marco, Vranckx, Pascal, Watanabe, Hirotoshi, Windecker, Stephan, Angiolillo, Dominick J.

“…For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y 12 receptor inhibitor, has been the gold standard…”
Get full text

Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study by Cannon, Christopher P, Dr, Harrington, Robert A, Prof, James, Stefan, MD, Ardissino, Diego, MD, Becker, Richard C, Prof, Emanuelsson, Håkan, MD, Husted, Steen, MD, Katus, Hugo, Prof, Keltai, Matyas, Prof, Khurmi, Nardev S, MD, Kontny, Frederic, MD, Lewis, Basil S, Prof, Steg, Philippe Gabriel, Prof, Storey, Robert F, MD, Wojdyla, Daniel, MSc, Wallentin, Lars, Prof

“…Summary Background Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of…”
Get full text

Treatment inequity in antiplatelet therapy for ischaemic heart disease in patients with advanced chronic kidney disease: releasing the evidence vacuum by Varian, Frances L., Parker, William A. E., Fotheringham, James, Storey, Robert F.

“…Chronic kidney disease (CKD) is a global health problem and an independent risk factor for cardiovascular morbidity and mortality. Despite evidence-based…”
Get full text

Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial by Storey, Robert F., MD, DM, Angiolillo, Dominick J., MD, Bonaca, Marc P., MD, MPH, Thomas, Mark R., MD, Judge, Heather M., PhD, Rollini, Fabiana, MD, Franchi, Francesco, MD, Ahsan, Arif J., MD, Bhatt, Deepak L., MD, MPH, Kuder, Julia F., MA, Steg, Philippe Gabriel, MD, Cohen, Marc, MD, Muthusamy, Rangasamy, MD, Braunwald, Eugene, MD, Sabatine, Marc S., MD, MPH

“…Abstract Background The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a…”
Get full text

Effect of genetic variations on ticagrelor plasma levels and clinical outcomes by Varenhorst, Christoph, Eriksson, Niclas, Johansson, Åsa, Barratt, Bryan J, Hagström, Emil, Åkerblom, Axel, Syvänen, Ann-Christine, Becker, Richard C, James, Stefan K, Katus, Hugo A, Husted, Steen, Steg, Ph Gabriel, Siegbahn, Agneta, Voora, Deepak, Teng, Renli, Storey, Robert F, Wallentin, Lars

“…Ticagrelor, a direct-acting P2Y12-receptor antagonist, is rapidly absorbed and partly metabolized to the major metabolite AR-C124910XX (ARC). To identify…”
Get full text

Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial by James, Stefan, MD, Åkerblom, Axel, MD, Cannon, Christopher P., MD, Emanuelsson, Håkan, MD, Husted, Steen, MD, Katus, Hugo, MD, PhD, Skene, Allan, PhD, Steg, Philippe Gabriel, MD, Storey, Robert F., MD, Harrington, Robert, MD, Becker, Richard, MD, Wallentin, Lars, MD

“…Background Antiplatelet therapy is essential treatment for acute coronary syndromes (ACS). Current therapies, however, have important limitations affecting…”
Get full text

Antiplatelet agents for the treatment and prevention of atherothrombosis by Patrono, Carlo, Andreotti, Felicita, Arnesen, Harald, Badimon, Lina, Baigent, Colin, Collet, Jean-Philippe, De Caterina, Raffaele, Gulba, Dietrich, Huber, Kurt, Husted, Steen, Kristensen, Steen Dalby, Morais, João, Neumann, Franz-Josef, Rasmussen, Lars Hvilsted, Siegbahn, Agneta, Steg, Philippe-Gabriel, Storey, Robert F, Van de Werf, Frans, Verheugt, Freek

“…The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American…”
Get full text

Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes by Storey, Robert F., MD, Husted, Steen, MD, Harrington, Robert A., MD, FACC, Heptinstall, Stanley, PhD, Wilcox, Robert G., MD, Peters, Gary, MD, Wickens, Mark, BSc, Emanuelsson, Håkan, MD, PhD, Gurbel, Paul, MD, FACC, Grande, Peer, MD, Cannon, Christopher P., MD, FACC

“…Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes…”
Get full text

Ticagrelor: clinical development and future potential by Sanderson, Nicholas C, Parker, William A E, Storey, Robert F

“…Platelets participate centrally in atherothrombosis, resulting in vessel occlusion and ischaemia. Consequently, optimisation of antiplatelet regimens has the…”
Get full text

Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial by Bonaca, Marc P., MD, MPH, Bhatt, Deepak L., MD, MPH, Braunwald, Eugene, MD, Cohen, Marc, MD, Steg, Philippe Gabriel, MD, Storey, Robert F., MD, Held, Peter, MD, PhD, Jensen, Eva C., MD, PhD, Sabatine, Marc S., MD, MPH

“…Background P2Y12 receptor antagonist therapy is recommended in addition to ASA for up to 1 year after acute coronary syndrome to reduce ischemic events. In…”
Get full text